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Another niche for Notch
GR Dressler1
The Notch signaling pathway patterns the developing nephron along 
the proximal–distal axis during renal development. In an adult acute 
tubular necrosis model, Kobayashi et al. now show expression of many 
Notch components and the activation of Notch target genes, suggesting a 
critical function for Notch in regenerating proximal tubules.
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One of the most striking themes to have 
emerged from the realm of developmen-
tal biology during the past 20 years is the 
conservation of signaling pathways that 
control growth, differentiation, pattern 
formation, and cell death in organisms 
as disparate as ﬂies and humans. But it is 
not only the conservation of receptors, 
ligands, and second messengers across 
hundreds of millions of years of evolution 
that is remarkable; it is also the variety of 
biological outputs that any given pathway 
can achieve. Indeed it appears that the 
same pathways are used over and over 
again often with quite diﬀerent results. Is 
there a developing organ system or cell 
type that does not utilize some aspect of 
WNT/β-catenin, transforming growth fac-
tor-β superfamily, ﬁbroblast growth factor, 
or hedgehog signaling? Given the diverse 
biological activities of these signaling mol-
ecules and receptors, we should not be sur-
prised that they are also implicated in many 
disease processes, from cancer to ﬁbrosis. 
The Notch signaling pathway falls squarely 
into that category of highly conserved and 
adaptive mechanisms whose functions in 
the developing and adult kidney are now 
being addressed.
The intricacies of Notch signaling are 
summarized in recent reviews that discuss 
not only the activation of receptors but the 
regulation of signaling by receptor–ligand 
secretion, modiﬁcation, and degradation.1,2 
A more simpliﬁed view of Notch signaling 
is presented in Figure 1, which also high-
lights a central theme: that the Notch path-
way requires direct cell–cell interactions. 
Signaling requires cell contact because both 
receptors and ligands are single-pass trans-
membrane proteins. In mammals, there 
are four receptors, called Notch-1 through 
Notch-4, and at least seven ligands, Delta-
1 through Delta-4, Jagged-1 and Jagged-2, 
and Serrate. Notch proteins are modiﬁed 
by the Fringe glycosyltransferases, which 
are thought to alter aﬃnity for diﬀerent 
ligands. Engagement of the Notch proteins 
by ligands results in a series of proteolytic 
processing events that remove first the 
extracellular domain, via metalloprotease 
cleavage, and then the intracellular domain, 
via the γ-secretase enzymatic complex. 
This liberated Notch intracellular domain 
(NICD) translocates to the nucleus and reg-
ulates gene expression through interactions 
with the Rel-family transcription factor Csl 
and the coactivator, Mastermind. Among 
the best-characterized targets of NICD 
activation are the Hes and Hey family of 
helix-loop-helix proteins, which are essen-
tial for regenerating stem-cell populations 
and for complex oscillatory mechanisms 
of embryonic segmentation.3 As an aside, I 
should mention that the γ-secretase enzy-
matic complex has been well characterized 
primarily because it is also responsible for 
cleaving the amyloid-β precursor protein 
to generate the plaques found in the cen-
tral nervous system of Alzheimer’s disease 
patients.
The biological eﬀects of activated Notch 
signaling play out in three conceptually dif-
ferent scenarios. The ﬁrst is called lateral 
inhibition, whereby a ﬁeld of equivalent 
cells is resolved into diﬀerent fates. This 
was originally described in the omma-
tidia of the ﬂy eye. Once small diﬀerences 
in Notch signaling are detected within 
a ﬁeld of cells, a single cell ampliﬁes the 
signal, is selected for a neuronal fate, and 
suppresses the neuronal fate of its neigh-
bors.4 A second eﬀect of Notch signaling 
is lineage decision making, which may 
have aspects of lateral inhibition but can 
also occur independent of the suppressive 
eﬀects associated with lateral inhibition. A 
well-studied example is the B- versus T-cell 
fate decision in the mammalian immune 
system.5 Lastly, Notch signaling can form 
boundaries or establish niches for main-
taining speciﬁc cell types. It is this ability 
to establish boundaries between regions 
fated to make diﬀerent cell types that may 
be most relevant to the kidney.
The ﬁrst direct evidence that Notch sig-
naling was important for boundary forma-
tion in the vertebrate kidney was found in 
the Xenopus pronephros, in which Notch 
activation appears to suppress nephric duct 
formation and promote pronephric tubule 
fates.6 More recently, the Drummond 
laboratory has shown that Jagged-2 and 
Notch-3 in the zebraﬁsh embryo promote 
diﬀerentiation of ion transport epithelia 
while suppressing the multiciliated epi-
thelial fates in a manner more reminiscent 
of lateral inhibition.7 In the mammalian 
kidney, several key papers from Kopan’s 
laboratory demonstrate the eﬀects of Notch 
signaling on proximal–distal axis speciﬁca-
tion in the developing nephron. Because of 
the variety of ligands and multiple Notch 
receptors expressed in the kidney, one way 
to completely inhibit signaling is through 
the use of γ-secretase inhibitors8 or the spe-
ciﬁc deletion of presenilin,9 the enzymatic 
subunit of the γ-secretase complex. Both 
of these experimental approaches pointed 
to a role for Notch in specifying the more 
proximal elements of the nephron during 
kidney development. These conclusions 
were conﬁrmed by the speciﬁc deletion of 
Notch-2 in the kidney,10 which resulted in 
the complete absence of glomerular epithe-
lia and proximal convoluted tubules, and is 
entirely consistent with the appearance of 
the NICD within the nuclei of proximal and 
glomerular epithelial precursor cells. Thus, 
Notch-2 signaling compartmentalizes the 
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developing nephron by specifying proxi-
mal cell fates and forming a boundary 
between these proximal and the more dis-
tal elements.
Why should Notch signaling in renal 
development be of interest to clinical 
nephrologists? As with most develop-
mental signaling pathways, Notch is reac-
tivated in renal injury. Kobayashi et al.11 
(this issue) show quite conclusively that 
Notch pathway receptors, ligands, and tar-
get genes are quickly upregulated in the rat 
kidney ischemia and reperfusion model 
of acute tubular necrosis. Furthermore, 
the ligand Delta-1 was shown to increase 
survival or proliferation of proximal 
tubule cells in vitro. Given that the proxi-
mal tubules are able to regenerate after 
ischemia or nephrotoxic injury, it is not 
surprising that many of the same signaling 
pathways that control diﬀerentiation, pro-
liferation, and survival during embryonic 
renal development are reactivated in the 
regenerating tubules. Early markers for 
regenerating renal epithelial cells include 
the transcription factor Pax2 and the sig-
naling proteins WNT4 and bone mor-
phogenetic protein 7 (BMP7). Indeed, the 
high levels of expression of BMP7 have 
prompted its use as an agonist of regen-
eration after acute injury.12 Whether the 
Notch pathway can be accentuated with 
recombinant proteins or small molecules 
in vitro remains to be determined. Nev-
ertheless, the data provided by Kobayashi 
et al.11 suggest that this is an important 
determinant of regenerated proximal 
tubule cell fate that could be stimulated 
under appropriate circumstances.
As is often the case, too much of a good 
thing may be detrimental. Although 
Notch is clearly essential for development 
and may play an important role in regen-
eration, stimulating the Notch pathway in 
healthy adult kidneys is likely to lead to 
complications. Evidence that Notch, Jag-
ged, and its transcriptional target Hey-1 
are complicit in the transforming growth 
factor-β-mediated transdiﬀerentiation of 
epithelial cells to a mesenchymal phe-
notype is compelling.13 This process of 
epithelial–mesenchymal transition is 
thought to contribute to glomerular and 
interstitial ﬁbrosis in both chronic and 
acute renal diseases. Consistent with 
the potential role for Notch in chronic 
disease, upregulation of Jagged and 
Hes-1 has been observed recently in dia-
betic nephropathy.14 The problem with 
these analyses is determining whether 
activation of Notch is a response to or 
a primary cause of the diseased state. 
Clearly, it will require using mutant mice 
or γ-secretase inhibitors in the various 
animal models of chronic and acute renal 
injury to deﬁnitively address the role of 
Notch in disease. If Notch activation is a 
compensatory or protective measure, it 
would make sense to develop strategies 
for activation of the pathway. This would 
most likely require small-molecule ago-
nists, as the endogenous ligands are large 
and unwieldy. If Notch activity contrib-
utes to chronic disease, then the use of 
γ-secretase inhibitors may prove protec-
tive. Unfortunately, given the activity of 
Notch signaling in other essential cell 
types, such as in the immune system, 
pleiotropic eﬀects of systemic inhibition 
may be unacceptable.
Whether or not Notch proves to be clini-
cally relevant, it is still remarkable how 
well the regenerating kidney recapitulates 
aspects of embryonic development. It is 
too bad that this capacity for regeneration 
is limited to proximal tubules. Now if we 
could only get the glomerulus to behave.
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Biotransformation enzymes 
in development of renal injury 
and urothelial cancer caused by 
aristolochic acid
M Stiborová1, E Frei2 and HH Schmeiser2
Ingestion of aristolochic acid (AA) is associated with the development 
of AA-nephropathy and Balkan endemic nephropathy, which are 
characterized by chronic renal failure, tubulointerstitial fibrosis, and 
urothelial cancer.  Understanding which enzymes are involved in AA 
activation and/or detoxification is important in assessing susceptibility 
to AA. Xiao et al. demonstrate that hepatic cytochrome P450s in mice 
detoxicate AA and thereby protect kidney from injury. The relative 
contribution of enzymes activating AA to induce urothelial cancer in 
humans remains to be resolved.
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The paper by Xiao et al.1 (this issue) 
addresses the interesting and still unset-
tled question of whether the metabolism 
of aristolochic acid (AA) determines 
its pathophysiological effects, and, if 
so, which enzymes participating in this 
process are responsible. AA, a naturally 
occurring nephrotoxin and carcinogen, is 
associated with urothelial cancer develop-
ment in patients suﬀering from Chinese 
herb nephropathy, now termed aristolo-
chic acid nephropathy (AAN), and may 
also be a cause of the development of a 
similar type of kidney ﬁbrosis with malig-
nant transformation of the urothelium, 
Balkan endemic nephropathy (BEN).2,3 
The molecular mechanisms for AA-medi-
ated renal injury, and whether it is an early 
stage of the urothelial-specific tumor 
development, are still matters of debate 
and need further investigations. In this 
context, it is noteworthy that a case of AA-
induced tumor development without renal 
injury4 suggests dissociation between 
AA-mediated nephrotoxicity and carci-
nogenicity. AA seems to directly cause 
renal injury by activating mitochondrial 
permeability transition, which was found 
recently in human renal tubular epithe-
lial cells,5 and metabolic activation of AA 
to species forming DNA adducts is an 
important step for AA-induced malignant 
transformation.3,6 Indeed, the molecular 
mechanism of AA-induced carcinogen-
esis demonstrates a strong association 
between DNA adduct formation, muta-
tion pattern, and tumor development.3 
The predominant AA-DNA adduct, 7-
(deoxyadenosin-N6-yl) aristolactam I 
(dA-AAI), which is the most persistent of 
the adducts in the target tissue, is a muta-
genic lesion leading to A→T transversions 
in the p53 gene in DNA from urothelial 
tumors of AAN and BEN patients.3,7
One of the common features of AAN 
and BEN is that not all individuals 
exposed to AA suﬀer from nephropa-
thy and tumor development. We have 
suggested earlier that one cause of 
these diﬀerent responses may be indi-
vidual diﬀerences in the activities of the 
enzymes catalyzing the biotransforma-
tion (detoxication and/or activation) 
of AA (for a summary, see Stiborová et 
al.6). Many genes of enzymes metabo-
lizing toxicants and carcinogens are 
known to exist in variant forms or show 
polymorphisms resulting in diﬀering 
activities of the gene products. These 
genetic variations appear to be impor-
tant determinants of cancer risk or other 
toxic eﬀects of xenobiotics.6
The proposed activation and detoxica-
tion pathways for the major component of 
AA, aristolochic acid I (AAI), are shown 
in Figure 1. AAI is activated by simple 
nitroreduction to N-hydroxyaristolactam 
I, which forms a cyclic N-acylnitrenium 
ion as the ultimate carcinogenic species 
binding to DNA. The most important 
human and rat enzyme activating AAI 
in vitro is hepatic and renal cytosolic 
NAD(P)H:quinone oxidoreductase 
(NQO1), followed by hepatic microsomal 
cytochrome P450 (CYP) 1A1/2 and renal 
microsomal NADPH:CYP reductase 
(CPR), besides prostaglandin H synthase 
(cyclooxygenase (COX)), which is highly 
expressed in urothelial tissue.6 It is of note 
that NQO1 polymorphism (the geno-
type NQO1*2/*2) was found to predis-
pose patients suﬀering from BEN to the 
development of urothelial malignancy of 
the upper urinary tract (odds ratio 13.75, 
95% conﬁdence interval 1.17–166.21).8 
This ﬁnding, together with the demon-
stration of the importance of NQO1 in 
AAI activation, could be an explanation 
for cancer induction by AAI in only some 
of the AAN and BEN patients.
The competing conversion of N-
hydroxyaristolactam I to the correspond-
ing 7-hydroxyaristolactam or its further 
reduction to aristolactam I should be 
considered a detoxication pathway; 
